AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis
The FDA granted an accelerated approval to AbbVie’s c-Met-directed ADC Emrelis as a new treatment option for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer who’ve previously received systemic therapy. The green light equips AbbVie with a second commercial ADC after Elahere, which it acquired in its $10.1 billion buyout of ImmunoGen.
The FDA granted an accelerated approval to AbbVie’s c-Met-directed ADC Emrelis as a new treatment option for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer who’ve previously received systemic therapy. The green light equips AbbVie with a second commercial ADC after Elahere, which it acquired in its $10.1 billion buyout of ImmunoGen.
